Previous phase I studies demonstrated safety and some beneficial effects of mesenchymal stem cells (MSCs) in patients with mild to moderate idiopathic pulmonary fibrosis (IPF). The aim of our study was to evaluate the safety, tolerability, and efficacy of a high cumulative dose of bone marrow MSCs in patients with rapid progressive course of severe to moderate IPF. Twenty patients with forced ventilation capacity (FVC) ≥40% and diffusing capacity of the lung for carbon monoxide (DLCO) ≥20% with a decline of both >10% over the previous 12 months were randomized into two groups: one group received two intravenous doses of allogeneic MSCs (2 × 10 8 cells) every 3 months, and the second group received a placebo. A total amount of 1.6 × 10 9 MSCs had been administered to each patient after the study completion. There were no significant adverse effects after administration of MSCs in any patients. In the group of MSC therapy, we observed significantly better improvement for the 6-minute walk distance in 13 weeks, for DLCO in 26 weeks, and for FVC in 39 weeks compared with placebo.
| INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is the most common of the interstitial lung diseases, a progressing chronic disease with unknown origin characterized by the development of fibrotic transformation of the lung parenchyma, predominantly in the older population. 1 The prevalence of IPF appears to be increasing, potentially explained by population aging. 2 The survival median of patients with IPF is 3 to 5 years; at the same time, the individual survival of patients may be extremely variable. [3] [4] [5] Conventionally, the IPF clinical course can be categorized into three types based on the rate of the forced ventilation capacity (FVC) decline: slow deterioration (less than 10% decline in FVC over 6 months or no changes in the disease indicators for many months), intermittent deterioration with episodes of exacerbations and rapid deterioration (more than 10% decline in FVC for 6 months). 3, 6, 7 For the last type, before the era of antifibrotic medications, the life expectancy of patients did not usually exceed 2 years from the time of diagnosis. [6] [7] [8] Besides acute exacerbations, a poor prognosis might be suspected in patients with IPF with such predictors as low values of FVC and diffusing capacity of the lung for carbon monoxide (DLCO), old age, and a high rate of pulmonary function decline. 3, 9 The majority of clinical studies on the drug therapy of IPF did not evaluate the pretreatment functional reduction rate 10, 11 ; therefore, it is difficult to judge its efficiency in patients with a fast lung function decline.
After a large number of successful preclinical studies, a treatment with mesenchymal stem cells (MSCs) is considered a potential new direction for lung fibrosis therapy. 12, 13 The potential effects of MSCs in pulmonary fibrosis are related to their ability to produce a large number of biologically active substances with anti-inflammatory, immunosuppressive, and angiogenic properties. 12 The results of the published clinical trials on the cell therapy for IPF confirmed the safety of MSCs; however, all of these studies included patients with mild to moderate impairment of lung function, without taking into account the rate of their preceding decline. Also, the total dose of administered cells did not exceed 2 × 10 8 . [14] [15] [16] We performed the first clinical trial in this field in patients who had a fast lung function decline, using a significantly more intensive intervention with respect to both the individual MSCs dose and the frequency of dose administration. Twenty patients were included into the study (age 33-74 years, 11 males, 9 females), all of whom had a histologically or radiologically confirmed pattern of usual interstitial pneumonia (UIP), with a history of a lung function decline (FVC or DLCO) ≥10% over the last 12 months and a current FVC ≥40% of predicted and DLCO ≥20% of predicted. The complete list of inclusion/exclusion criteria is shown in Supporting Information Appendix S1. According to the study protocol, those patients that met the eligibility criteria were randomized into two groups, with 10 patients per group: group 1 received four series of MSCs intravenous infusions, repeated after 12 weeks. Each of the series included two intravenous infusions performed in a 7-day interval. Each infusion contained a suspension of 200 million cells in 400 mL of normal saline. The last MSCs administration was performed at 39 weeks after the study beginning. The total number of MSCs administered in group 1 was 1.6 × 10 9 for the patients who completed the protocol. Group 2 received a placebo (400 mL of normal saline) with the same schedule. Sixteen patients completed the study ( Figure 2 ). The total characteristics of enrolled patients in each group are presented in Table 1 . None of the patients took antifibrotic drugs because of their inaccessibility in the country during the study. Most of patients took prednisone as a single drug approved by the current
Lessons learned
• The primary objective was the evaluation of the safety and tolerability of repeated infusions of high doses of bone marrow-derived MSCs up to the total cumulative dose of 2 billion cells in subjects with rapidly progressing idiopathic pulmonary fibrosis.
• The evaluation was based on the number and severity of AEs related to the infusion during 52 weeks of follow-up.
• The secondary objective was evaluation of the main lung function parameters, such as forced ventilation capacity and diffusing capacity of the lung for carbon monoxide.
• The stem cell treatment has been found safe and well tolerable.
• Patients in the main group had their lung function increased, as compared to the placebo group, in which the continued decline of the lung function was observed.
• These findings allow us to conclude that such stem cell therapy is effective for the treatment of rapidly progressing idiopathic pulmonary fibrosis.
Significance statement
The results of this first-in-human clinical trial revealed that a high cumulative dose of mesenchymal stem cells (MSCs) is safe and well tolerated by patients with idiopathic pulmonary fibrosis with a rapid lung function decline. During the treatment period, the patients in the main group experienced increased lung function; however, the patients in the placebo group experienced a continued decline in lung function. Thus, this study shows the safety, tolerability, and potential benefits of greater doses of MSCs than those used earlier in patients with idiopathic pulmonary fibrosis, and these findings might move future trials toward a new step in stem cells transplantation. national guidelines. The diagnosis of IPF was based on the results of a multidisciplinary discussion (MDD) according to American Thoracic Society/European Respiratory Society criteria. 1 week 26 and 52. Spirometry and diffusion tests were conducted in accordance with european respiratory society (ERS)/american thoracic society (ATS) regulations. 17, 18 The 6MWTD was performed according to the АТS protocol. 19 A semiquantitative assessment of the HRCT pulmonary fibrosis score was performed by two independent radiologists using the method of Oda et al. 20 
| MSCs preparation

| Isolation of human MSCs
For half of the patients (n = 5), the bone marrow for MSCs separation was obtained from young (20-35 years of age), healthy blood relatives. In cases of the absence of young, healthy relatives or their refusal (n = 5), we used the bone marrow from healthy donors with the same sex as the patient. In these cases, donors for each MSC injection were randomized. Each donor signed the informed T A B L E 1 Descriptive statistics for the groups at the baseline point* was used for the image capture.
| Karyotyping
Karyotypes were analyzed in MSCs from the first and the last (4 or 5)
passages that were isolated and cultured in vitro using the chromosome multicolor fluorescence in situ hybridization (mFISH) technique. 22 The cells were incubated for 4 h with colchicine (40 μg/mL), and then the cells were incubated in 0.075% KCl fixed with Carnoy's solution ThermoFisher). ote: There were no significant differences between the study groups compared using the general linear model. Abbreviations: AEs, adverse events; IPF, idiopathic pulmonary fibrosis; LRTI, lower respiratory tract infection; URTI, upper respiratory tract infection.
| Statistical analysis
HRCT-based fibrosis score was calculated in accordance with the recommendations by Kundel and Polansky, using Cohen's kappa coefficient with 95% confidence limits. 23 Figure 1E ).
Thus, the characterization of cells prior to administration revealed that we obtained three potent MSCs with normal diploid karyotype and a high level of expression of MSC-specific surface markers. Adverse effects were more frequently observed in the group receiving MSCs; among them were fever and chills, predominantly in the first day after infusion (Table 2 ). However, these reactions were mild and did not require study discontinuation. Light fever after an intravenous cell infusion was noted at least once over the whole study duration in 4 out of 10 patients. One female patient in the MSCs therapy group developed an ischemic stroke, with almost all sensory and motor functions restored after anticoagulant and vascular therapy. In the placebo group 1, one male patient suffered an exacerbation of IPF; no exacerbations were detected in the MSCs group.
| Safety
The statistical analysis did not reveal any therapy-associated significant AEs ( Table 2) .
F I G U R E 3 Secondary endpoints dynamics. A-C, Differences (delta) of real values (y-axis) of forced ventilation capacity (FVC; A)
, diffusing capacity of the lung for carbon monoxide, B, and 6MWD, C, from the baseline level, during the treatment period (median, minimum and maximum, 25% and 75% quartiles are shown). D, Change from the baseline in FVC median (% of predicted) during 12 months before the treatment and during the treatment (by week 52) in the main group and the control. In the legend, 3, 6, 9, and 12 mean the values after 3, 6, 9, and 12 months, respectively
| Overall effects of MSCs versus placebo
After the first 3 months of treatment (administration of 400 million MSCs), we did not observe a statistically significant difference between the groups with regard to any of the studied indices, except for the 6MWTD, which increased by 15.3% in the MSCs group and decreased by 2.7% in the placebo group (Table 3) . By the sixth month of the therapy, the MSCs group showed a significantly better DLCO change (−1.2% in the MSCs group vs −6.5% in the placebo group) and 6MWTD (+22.0% vs −3.4% in the placebo group) compared with baseline. After 9 months, and a total cell dose of 1.2 × 10 9 , the difference in the dynamics from baseline points was observed in FVC (+4.7% vs −7.6%) and 6MWDT (+24.2% vs −6.7%). After the treatment completion and reaching the total dose of 1.6 billion MSCs after 12 months (by week 52), statistically significant differences were observed in the dynamics of FVC (+3.7% vs −9.5%), DLCO (−5.1% vs −12.9%), and 6MWDT (+26.6% vs −9.8%) from the baseline ( Figure 3A-C) .
The interobserver agreement (κ value) in the HRCT signs estimation was in general high and determined as 0.69 for the reticular changes, 0.75 for the traction bronchiectasis, 0.85 for the normal attenuation, and 0.88 for the honeycombing. The HRCT fibrosis score did not differ significantly from the baseline by week 26 (0.7% for MSCs vs 0% for placebo) and by week 52 (1.7% for MSCs vs 0.7% for placebo).
When evaluating the FVC decline for the 12 months preceding randomization and during the 52 weeks of the therapy, we found a significant improvement in the group receiving MSCs (from −13.8% to +3.7%)
as compared with the placebo group (from −11.7% to −9.5%; Figure 3D ). We analyzed individual patients in the MSCs therapy group, who had a continuing decline of FVC and DLCO >10% over the observation period (patients 4 and 5), as well as deceased patients (patients 9 and 10). All patients with no response to the therapy were females, had the longest disease history (48-84 months), and had low body mass index (BMI; three out of four had a BMI of 18 to 19 kg/m 2 , one a BMI of 22 kg/m 2 ) and a low initial level of DLCO (<30% of predicted).
| DISCUSSION
The presented clinical study was the first one in which the effects of intravenous MSCs transplantation in patients with rapidly progressing IPF were compared with the effects of a placebo and significantly higher and more frequent doses of cell infusions than those in the previous investigations were applied. The study demonstrated the safety of a total dose of 1.6 × 10 9 cells, which all the participants of active group having completed the study received. Although the incidence of side effects was more frequent in the MSC therapy group than in the placebo group, they did not have severe manifestations, and the statis- infusion. 24 Previously, the highest MSCs dose applied in humans was recorded in the clinical study by Patila et al in patients with ischemic heart failure, in which up to 1.35 × 10 9 autologous stem cells were administered transmyocardially without any serious adverse events (SAEs). 25 The issue of safety and tolerance of such high doses is important to consider; although almost all the clinical studies in the field of intravenous MSCs transplantation confirmed the absence of notable adverse effects, most studies used allogeneic cells from one donor, whereas we applied cells from different donors to one and the same patient. 26 It is not improbable that the higher observed incidence of effects like fever and chills, which are rarely seen in other studies, is related to this fact. Nevertheless, Tzouvelekis et al registered a temperature elevation in 50% of patients after endobronchial administration of 0.5 × 10 6 per kilogram of body weight adiposederived MSCs. 15 A transitory fever was also one of the most frequent SAEs after intravenous infusions of allogeneic MSCs in the treatment of some nonpulmonary diseases. 27, 28 The other observed adverse effects were similar in incidence between the placebo group and the cell therapy group. One female patient, 73 years of age, suffered an ischemic stroke at day 29 after the first two MSCs infusions; however, we cannot relate this event to the therapy.
The level of mortality did not differ between the study groups: two patients died in each group, and all the cases were the most severe ones with the lowest functional characteristics, were oxygen-dependent, and had comorbidities including pulmonary hypertension, ischemic heart disease, and chronic obstructive pulmonary disease. Of five included patients with an initial DLCO <25% of predicted and 6MWDT <150 m, four died after four cell (8 × 10 8 ) or placebo infusions. We believe that cell therapy might be ineffective at this advanced stage of the disease.
Our data differ from the results of Chambers et al, 14 Score of 30%, 36%, and 45% and of the Sequential Organ Failure Assessment Score of 4%, 23%, and 48%, respectively. 24 In patients with ischemic heart disease, a dose of fewer than 50 million cells did not significantly affect the estimated parameters, whereas doses of 50 to 100 million and 100 to 250 million cells resulted in a boost of the left ventricular (LV) ejection fraction and LV end-systolic volume. 29 This is explainable, because the paracrine effect of transplanted MSCs is currently suggested as their most probable mechanism of action: MSCs and their condition media can cause an antifibrotic effect via suppression of apoptosis of epithelial and endothelial cells, deceleration of epithelial-mesenchymal transition, and suppression of activated fibroblasts and inflammatory response due to their own secretion of antiinflammatory cytokines and chemokines, adhesion molecules, growth factors, and so forth. [30] [31] [32] [33] Interestingly, in the therapy group, no episode of acute exacerbation was registered in any of the patients for the year-long follow-up period ( Figure 3D ). This fact allows an assumption that the MSC therapy with Certain concerns with the MSC therapy are related to its potential ability to intensify fibrogenesis in the lungs. Indeed, a possibility has been shown for differentiation of fibrocytes (of the MSC subpopulation circulating in the blood) into fibroblasts/myofibroblasts. 34 The increase of the MSC level in the bronchoalveolar lavage (BAL) liquid is a predictor of bronchiolitis obliterans development in the transplanted lungs. 35 In our study, we did not measure the levels of fibrocytes in the blood and MSC in the BAL liquid; however, we did not find radiological signs of fibrosis in the active therapy group.
The HRCT-based fibrosis score did not show statistically significant differences between the study group and the placebo group. This might be due to either the small number of study participants or the fact that the cell therapy effects are realized predominantly at the functional level. The increase of the lung diffusion capacity as well as the significant increase of 6MWDT may also reflect the latter consideration. One The proangiogenic mechanism of the MSC effect is verified by the data obtained in the animal models of diabetes, physical overexertion, and diaphragm dysfunction, demonstrating that administration of different MSC types resulted in augmented angiogenesis in the muscle tissue, increase in the blood flow, and enhancement of the mitochondrial reserve and muscle function. [36] [37] [38] [39] The proangiogenic potential is also confirmed by the recent proteomic studies showing overexpression of the proteins associated with angiogenesis in the MSCs' secretome, the angiogenic effect being proved with the tube formation assay. 40 It is of note that many proangiogenic factors are simultaneously anti-inflammatory; therefore, the classic point of view on the MSCs as inducers of only anti-inflammatory cytokines probably requires reconsideration. 40 It should be noted that the proangiogenic MSC effect in patients with IPF is only our hypothesis made in an attempt to explain the obtained positive effects in this pilot study and is based only on the previously published studies of MSCs.
Interestingly, a MSCs mixture from different donors demonstrates a higher immunosuppressive activity than a cell pool from one donor. 41 This is probably related to a significant individual variability of both the proliferative and immunotropic potentials of MSCs obtained from different donors. 42 However, because we used in our study young, healthy relatives as donors, we decided to not use the mixture of MSCs from different donors. For those patients to whom we administrated MSCs from nonrelatives, donors for each injection have been randomized. To minimize the risk of using MSCs with "weak" regenerative properties, we conducted the immunophenotype and differentiation analyses of cells from each donor. We also did not use MSCs with low proliferative capacity and MSCs from more than the fifth passage.
All patients in the current study had a higher rate of FVC decline (−10.5%) per year at the moment of inclusion into the study than those in the average population of patients with IPF (−6.2%). 4,10 Thus, for the first time, we performed a study of the effects of MSCs transplantation in patients with IPF with the most aggressive course of the disease and the poorest prognosis. Moreover, our patients in general belonged to a more severely impaired functional category than those who participated in studies of the antifibrotic drugs nintedanib and pirfenidone, which were approved for IPF treatment. 10, 11 One unusual case, a 33-year-old man, a surgeon, with HRCT findings of definite UIP, without a history of smoking and exposure to environmental pollutants, and with negative tests for autoimmunity, underwent a video-assisted thoracoscopic surgery. The lung biopsy revealed the morphologic pattern of UIP, and MDD confirmed the diagnosis of IPF despite the young age.
The limitations of the current study include a small number of study participants as well as performance of treatment at a single center, which may explain the observed oscillations in the dynamics of certain indices (eg, substitution of an increase in DLCO by a decrease between 26 and 39 weeks) as well as the absence of significant differences in the fibrosis score assessment based on the HRCT data. Furthermore, the procedure was not blind for the researchers. We also could not investigate the distribution and survival of the transplanted cells in the recipients' bodies, their influence on the cytological analysis of the BAL fluid, or biomarkers of the fibrotic activity.
| CONCLUSION
We have shown in this study that high cumulative dose of transplanted bone marrow-derived MSCs is safe and well tolerated.
The safety of the MSCs therapy has been proved by the fact that even application of an extremely high dose of stem cells (the highest one on the record) has not been associated with any significant adverse effects, except for a transitory fever during the first day after the infusion noted in 4 out of 10 patients. During the treatment period, patients in the main group had their lung function increased, as compared with the baseline and the same parameters in the placebo group, in which the continued decline of lung function was observed. Thus, we state the safety, tolerability, and potential benefits of greater doses of MSCs than those used earlier in patients with IPF and other pulmonary diseases, and these findings can move future trials toward a new step in stem cells transplantation. 
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